Table 1.

Association between heterozygous and homozygous CHD1 deletions and prostate cancer phenotype in all cancers as well as in the subsets of ERG-negative and ERG-positive cancers

CHD1 deletion
All cancers (N = 2,093)ERG fusion-negative cancers (n = 985)ERG fusion-positive cancers (n = 1,108)
nHetero. del. (%)Homo. del. (%)PnHetero. del. (%)Homo. del. (%)PnHetero. del. (%)Homo. del. (%)P
All samples20936.72.098510.94.111083.00.2
Tumor stagepT212685.02.00.00646438.43.60.05496251.40.30.0002
pT3a4226.92.116415.25.52581.60.0
pT3b26811.62.211414.95.31549.10.0
pT42913.80.01414.30.01513.30.0
Gleason score≤3+38484.60.9<0.00014457.41.4<0.00014031.50.50.0123
3+48975.92.136411.05.25332.40.0
4+320713.05.810018.012.01078.40.0
≥4+43721.62.72626.93.9119.10.0
Nodal stagepN010647.72.90.14547713.06.30.15085873.40.20.7578
pN > 0659.20.03013.30.0355.70.0
PSA level (ng/μL)< 42976.42.00.44061399.44.30.56971583.80.00.6786
4–1010875.71.85029.83.45852.20.3
10–204157.73.120812.06.32073.40.0
>201498.11.36713.43.0823.70.0
Surgical marginNegative15535.82.10.18217449.54.00.26238092.40.30.2235
Positive4348.31.819013.74.22444.10.0